Skip Navigation

Cardiovascular Research 2005 66(3):427-429; doi:10.1016/j.cardiores.2005.03.021
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Laufs, U.
Right arrow Articles by Böhm, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laufs, U.
Right arrow Articles by Böhm, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Cardiac effects of statins–advancements and open questions

Ulrich Laufs and Michael Böhm*

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, 66421 Homburg, Germany

* Corresponding author. Tel.: +49 6841 16 3000. Email address: ulrich@laufs.com

Received 11 March 2005; accepted 29 March 2005

The first 10% of the full text of this article appears below.

See also article by Di Napoli et al.[8] (pages 462-471) in this issue.

The beneficial vascular effects of statins are important for the primary and secondary prevention of coronary heart disease and stroke; however, their cardiac effects are less clear. In addition to their lipid-lowering properties, statins have been shown to exert extrahepatic, cholesterol-independent effects in animal studies that have been called "pleiotropic" effects. There is indirect evidence from human studies suggesting that pleiotropic action may contribute to the reduction of clinical endpoints by statin treatment (for review see [1]). These data are important because in addition to the advancement of our understanding of cardiovascular pathophysiology, they imply that patients at risk for adverse cardiovascular events may benefit from statins irrespective of their cholesterol levels [2].

In experimental models of ischemia and reperfusion, statins have been shown to limit the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
U Laufs, F Custodis, and M Bohm
Who does not need a statin: too late in end-stage renal disease or heart failure?
Postgrad. Med. J., April 1, 2009; 85(1002): 187 - 189.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
U Laufs, F Custodis, and M Bohm
Who does not need a statin: too late in end-stage renal disease or heart failure?
Heart, September 1, 2008; 94(9): 1138 - 1140.
[Abstract] [Full Text] [PDF]